With box warnings

Without box warnings

Branded

Generic

3 results

herceptin
(Trastuzumab)
Genentech, Inc.
Usage: Herceptin is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer in combination with paclitaxel, or as a single agent after previous regimens. It is also used with cisplatin and capecitabine for HER2-positive metastatic gastric cancer. Patient selection should utilize an FDA-approved diagnostic.
herzuma
(TRASTUZUMAB)
Cephalon, Inc.
Usage: HERZUMA is indicated for adults with HER2 overexpressing breast cancer, both in adjuvant and metastatic settings, and for metastatic gastric or gastroesophageal junction adenocarcinoma. Treatment modalities include combinations with specific chemotherapies or as a single agent, guided by FDA-approved diagnostics.
trazimera
(trastuzumab-qyyp)
Pfizer Laboratories Div Pfizer Inc
Usage: TRAZIMERA is indicated for adjuvant treatment of HER2-overexpressing breast cancer (both node-positive and node-negative) and for metastatic breast cancer (in combination with paclitaxel or as a single agent). It is also indicated for HER2-overexpressing metastatic gastric cancer, used with cisplatin and capecitabine or 5-fluorouracil.

Medications for Metastatic Gastric Adenocarcinoma

herceptin